Moderna, Inc. $MRNA Shares Purchased by Neuberger Berman Group LLC

Neuberger Berman Group LLC raised its position in Moderna, Inc. (NASDAQ:MRNA) by 28.9% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 79,480 shares of the company’s stock after purchasing an additional 17,843 shares during the period. Neuberger Berman Group LLC’s holdings in Moderna were worth $2,053,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Norges Bank purchased a new position in shares of Moderna in the second quarter worth about $94,910,000. Federated Hermes Inc. raised its holdings in Moderna by 364.5% in the 2nd quarter. Federated Hermes Inc. now owns 2,869,271 shares of the company’s stock valued at $79,163,000 after acquiring an additional 2,251,497 shares during the last quarter. Geode Capital Management LLC lifted its stake in Moderna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock worth $244,458,000 after purchasing an additional 1,420,690 shares in the last quarter. Vanguard Group Inc. lifted its stake in Moderna by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock worth $1,150,743,000 after purchasing an additional 1,312,192 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Moderna by 20.7% during the 2nd quarter. Invesco Ltd. now owns 7,101,032 shares of the company’s stock worth $195,917,000 after purchasing an additional 1,217,408 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MRNA. Jefferies Financial Group set a $37.00 price objective on Moderna and gave the stock a “hold” rating in a research report on Tuesday. Piper Sandler raised their target price on Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research note on Monday, February 23rd. TD Cowen reiterated a “hold” rating on shares of Moderna in a report on Thursday, January 29th. Morgan Stanley set a $30.00 price target on shares of Moderna in a research report on Monday, February 16th. Finally, Royal Bank Of Canada raised their price objective on shares of Moderna from $25.00 to $30.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $32.33.

Moderna Stock Down 2.4%

Shares of NASDAQ:MRNA opened at $52.52 on Friday. The business has a 50-day moving average price of $43.13 and a 200 day moving average price of $32.26. The company has a current ratio of 3.29, a quick ratio of 3.22 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $20.74 billion, a price-to-earnings ratio of -7.22 and a beta of 1.29. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $59.55.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, February 13th. The company reported ($2.11) EPS for the quarter, beating analysts’ consensus estimates of ($2.79) by $0.68. The company had revenue of $678.00 million for the quarter, compared to analysts’ expectations of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. Moderna’s revenue for the quarter was down 33.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.91) earnings per share. Sell-side analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Settlement clears legal overhang: Moderna reached deals to resolve long‑running LNP patent litigation, which investors interpret as removing a major uncertainty that had been capping the stock. The market initially reacted positively to news the dispute is resolved. Moderna to pay up to $2.25B to end mRNA vaccine patent fight Moderna fronts $950M to settle yearslong COVID patent litigation
• Positive Sentiment: Bullish options flow: Unusually heavy call buying (112,509 calls, ~32% above typical volume) signals short‑term bullish positioning by traders and could support intraday upside if flows continue. (No external link provided)
• Positive Sentiment: Retail interest and momentum: Retail chatter and short‑term momentum have helped lift the stock recently (double‑digit weekly moves and large YTD gains cited by coverage), which can amplify volatility around news. Reddit Traders Are Cheering Moderna While Bears Watch the Cash Burn
• Neutral Sentiment: Analyst and narrative pieces: Several outlets are revisiting Moderna’s investment case (pipeline potential, oncology vaccine upside) and whether today’s price is a buying opportunity — useful context but not immediate catalysts. Moderna Stock (MRNA): Is It a Buy Now?
• Neutral Sentiment: Market bounce context: Coverage grouping Moderna with other volatile names notes technical bounces and differing Wall Street views — helpful for traders but mixed for longer‑term investors. These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next
• Negative Sentiment: Regulatory uncertainty: Reports highlighting recent FDA reversals and tougher scrutiny on new drug applications have increased investor concern that future approvals (e.g., respiratory or flu programs) could face delays or setbacks. That regulatory risk is pressuring the stock today. FDA reversals leave investors worrying about the fates of other experimental drugs
• Negative Sentiment: Cash/cost impact of the settlement: While the settlement removes legal overhang, it carries a material cash burden (Moderna may pay up to ~$2.25B and is fronting $950M), which renews concerns about cash burn and near‑term finances—an important negative for fundamental investors. Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology

Insider Activity at Moderna

In other news, President Stephen Hoge sold 160,009 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the completion of the transaction, the president directly owned 1,457,427 shares in the company, valued at $71,180,734.68. This trade represents a 9.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Noubar Afeyan sold 23,853 shares of Moderna stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the sale, the director directly owned 3,924 shares of the company’s stock, valued at $115,679.52. The trade was a 85.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 184,366 shares of company stock worth $8,531,936. Company insiders own 10.90% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.